Healthcare

HB 5074 changes how revenue from West Virginia's medical cannabis program is allocated. For fiscal year 2026, it directs $3 million to the Supreme Court for a child protection pilot, $10 million each to West Virginia University and Marshall University for ibogaine research, and $5 million to homelessness services, with remaining funds reverting to general revenue. Starting July 1, 2026, annual allocations will be: 15% to the Medical Cannabis Bureau for administration, 15% to the Department of Agriculture for cannabis testing, and 45% split among the Fight Substance Abuse Fund (20%), university research (10% each to Marshall and WVU), a Child Protection Commission (10%), and law enforcement training programs (40%). These changes apply to ongoing revenue from medical cannabis taxes, not new taxes or fees.

HB 5260 adds "edible" as an allowable form of medical cannabis in West Virginia, with strict requirements for safety and regulation. It requires processors to obtain bureau approval for each edible product, mandates specific shapes (like squares or circles), limits edibles to lozenges or gelatins, and caps THC content at 10mg per serving with a 15% potency variance. The bill prohibits color additives in edibles and requires all medical cannabis dispensing to be reported to the state's controlled substance monitoring database. This directly affects patients using medical cannabis, caregivers, and licensed processors who must comply with these new edible-specific rules.

HB 4629 amends West Virginia's tobacco sales law to allow institutions of higher education to distribute tobacco cessation products to individuals aged 18-21 for research purposes. This directly affects college/university research programs approved by institutional review boards (IRBs) that study tobacco cessation or prevention. The key provision creates an exception to the general 21+ age restriction, requiring all such distributions to occur within medically supervised, IRB-approved research programs. The bill changes the policy by permitting this specific age group access for legitimate medical research, while maintaining penalties for unauthorized sales to minors.